Methods for modulating the axonal growth of central nervous system neurons
Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous system neurons are also provided. Finally, a packed formulation comprising a pharmaceutical composition comprising an inosine nucleoside and a pharmaceutically acceptable carrier packed with instructions for use of the pharmaceutical composition for treatment of a central nervous system disorder is provided.
1. A method for stimulating axonal outgrowth of central nervous system neurons in a mammal with a central nervous system injury, comprising injection of the mammal with a pharmaceutical composition consisting essentially of an effective amount of inosine to thereby contact the injured central nervous system neurons with the inosine, such that axonal outgrowth is stimulated.
2. A method for stimulating axonal outgrowth of central nervous system neurons in a mammal with a central nervous system injury, comprising, injection of the mammal with a pharmaceutical composition that consists of inosine and a pharmaceutically acceptable carrier, to thereby contact the injured central nervous system neurons with the inosine, such that axonal outgrowth is stimulated.
3. A method of treating a mammal having suffered a central nervous system injury, comprising injecting the mammal with a pharmaceutical composition consisting essentially of an effective amount of inosine to thereby contact the injured central nervous system neurons with the inosine, such that axonal outgrowth is stimulated.
4. A method of treating a mammal having suffered a central nervous system injury, comprising injecting the mammal with a pharmaceutical composition consisting of an effective amount of inosine to thereby contact the injured central nervous system neurons with the inosine, such that axonal outgrowth is stimulated.
5. The method of claim 1 or 2 , wherein the pharmaceutical composition contacts the injured CNS neurons in vivo with a concentration of inosine of 5 uM to 1 mM.
6. The method of claim 1 or 2 , wherein the mammal is a human.
7. The method of claim 1 2 , 3 , or 4 , wherein the central nervous system injury is spinal cord injury, traumatic brain injury, or stroke.
8. The method of claim 7 wherein the spinal cord injury is selected from the group consisting of monoplegia, diplegia, paraplegia, hemiplegia and quadriplegia.